Report Overview
The point of care diagnostic market is forecast to grow at a CAGR of 6.0%, reaching USD 52.11 billion in 2031 from USD 38.94 billion in 2026.
Highlights:
- 1The market is expanding rapidly as portable devices enable testing closer to patients at home and clinics.
- 2Healthcare providers are shifting diagnostics from laboratories to bedside settings to reduce errors and speed decisions.
- 3Rising chronic and infectious diseases are driving strong demand for quick point-of-care testing worldwide.
- 4Manufacturers are innovating connected solutions and launching new systems to improve glucose and disease management.
The point-of-care diagnostics market is regarded as bedside testing which is known to be any form of diagnostic test that is performed in a laboratory. Point-of-care testing is done close to the patient but with the advent of modern medical advances, this type of testing has been made feasible to quickly and easily access a wide range of health factors to make the evaluation, diagnosis, prognosis, and screening as efficient as possible.
Point-of-care testing is essential in lowering the risk of potential errors which has resulted in the demand for point-of-care diagnosis increasing significantly both within and outside the hospital environment. A few factors such as the increased availability of portable, hand-held, and transportable devices have significantly attributed to the shift of testing from hospitals to even at home, emergency care, and even inconvenience clinic.
The growing prevalence of cardiovascular diseases and even diabetes in a few emerging nations such as China and India have further resulted in an increase in the demand for point-of-care diagnostics. For instance, according to the international diabetes federation in 2021, globally there were nearly 537 million adults belonging to the age group of 20 to 79 years living with diabetes globally.
Point of Care Diagnostic Market Driver:
Increasing prevalence of infectious and chronic diseases
Point-of-care tests have resulted in improving the management of infectious diseases, especially in developing regions but access to proper healthcare is a challenge. According to UNAIDS, around 20.6 million people in 2019 were living with HIV and 2.1 million people in India would be infected with HIV. Therefore, a high prevalence of HIV in the regions is likely to boost the demand for point-of-care diagnostics which is expected to accelerate the treatment of HIV infection
According to the World Health Organization, India accounts for the highest tuberculosis burden with an estimated incident of 2.64 million cases in 2020. In the year 2020, an estimated 15,898 people in Brazil would regard it to be at a strong risk of zika virus infections down over 30,000 cases which were reported in 2019.
An Increase in the occurrence rate of disorders is yet another critical factor that is fueling the demand for the point-of-care diagnostics market. For instance, according to CDC, worldwide approximately four to five million children develop respiratory syncytial virus and lower respiratory tract infections at least once a year.
Point of Care Diagnostic Market Geographical Outlook:
North America is estimated to grow significantly during the forecast period
North America is anticipated to grow significantly in the forecast period. An increase in the number of Covid-19 cases in the region is regarded to be a factor that is driving the growth of the point of care diagnostics market in the North American region.
Moreover, an increase in product innovations and the growth which can be seen in incidents of infectious and chronic disorders will also result in driving market growth in North America. USA and Canada are regarded to be key marketplaces responsible for regional market development.
Furthermore, this region has witnessed various governmental efforts leading to an increase in awareness about the early detection of regular health check-ups and diseases which is further leading to the promotion of point of care devices. Along with this, an increase in healthcare expenditures, a growth in the number of hospitals and even clinically diagnostic laboratories, and an increase in demand for collaborations among multiple players in the North American region is also expected to drive the market growth.
Point of Care Diagnostic Market Key Developments:
In January 2022, Roche launched its Cobas Pulse System in countries accepting the CE mark. This is Roche Diagnostics’ newest generation of connecting point-of-care solutions for professional blood glucose management.
Point of Care Diagnostic Market Scope
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 38.94 billion |
| Total Market Size in 2031 | USD 52.11 billion |
| Forecast Unit | Billion |
| Growth Rate | 6.0% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Testing, Platform, Mode, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|
Market Segmentation
By Testing
By Platform
By Mode
By End-user
By Geography
Table of Contents
1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. POINT OF CARE DIAGNOSTICS MARKET BY TESTING
5.1. Introduction
5.2. Cardio-Metabolic Monitoring Kits
5.3. Infecious Disease Testing Kits
5.4. Glucose Monitoring Kits
5.5. Coagulation Monitoring Kits
5.6. Tumor/Cancer Marker
5.7. Pregnancy & Fertility Testing
5.8. Urinalysis Testing Kit
5.9. Hematology Testing
5.10. Others
6. POINT OF CARE DIAGNOSTICS MARKET BY PLATFORM
6.1. Introduction
6.2. Lateral Flow Assay
6.3. Dipsticks
6.4. Microfluids
6.5. Molecular Diagnostics
6.6. Others
7. POINT OF CARE DIAGNOSTICS MARKET BY MODE
7.1. Introduction
7.2. Prescription
7.3. Over-The-Counter (OTC)
8. POINT OF CARE DIAGNOSTICS MARKET BY END-USER
8.1. Introduction
8.2. Hospitals
8.3. Diagnostics Centers
8.4. Others
9. POINT OF CARE DIAGNOSTICS MARKET BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. USA
9.2.2. Canada
9.2.3. Mexico
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Others
9.4. Europe
9.4.1. Germany
9.4.2. France
9.4.3. United Kingdom
9.4.4. Spain
9.4.5. Others
9.5. Middle East and Africa
9.5.1. Saudi Arabia
9.5.2. UAE
9.5.3. Others
9.6. Asia Pacific
9.6.1. China
9.6.2. India
9.6.3. Japan
9.6.4. South Korea
9.6.5. Indonesia
9.6.6. Thailand
9.6.7. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. Abbott Laboratories
11.2. Becton, Dickinson and Company
11.3. Biosynex
11.4. Danaher Corporation
11.5. EKF Diagnostics
11.6. Nova Biomedical
11.7. Quidel Corporation
11.8. Siemens AG
11.9. Trinity Biotech
11.10. WerfenLife S.A
12. APPENDIX
12.1. Currency
12.2. Assumptions
12.3. Base and Forecast Years Timeline
12.4. Key benefits for the stakeholders
12.5. Research Methodology
12.6. Abbreviations
Navigate
Trusted by the world's leading organizations
